Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma

Taku Fujimura, Yota Sato, Kayo Tanita, Chinbing Lyu, Yumi Kambayashi, Ryo Amagai, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Hiroo Hata, Takeru Funakoshi, Yumi Nonomura, Ryota Tanaka, Hisako Okuhira, Naoko Wada, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journalArticle

Abstract

Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

Original languageEnglish
Article number86
JournalFrontiers in Medicine
Volume6
Issue numberAPR
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Melanoma
Immunotherapy
Serum
Programmed Cell Death 1 Receptor
Biomarkers
Skin
Antibodies
Tumor Burden
nivolumab
Mutation
Therapeutics
Neoplasms
ipilimumab

Keywords

  • Baseline levels of CXCL5
  • Melanoma
  • Nivolumab
  • Nivolumab and ipilimumab combined therapy
  • Prediction of efficacy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fujimura, T., Sato, Y., Tanita, K., Lyu, C., Kambayashi, Y., Amagai, R., ... Aiba, S. (2019). Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma. Frontiers in Medicine, 6(APR), [86]. https://doi.org/10.3389/fmed.2019.00086

Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma. / Fujimura, Taku; Sato, Yota; Tanita, Kayo; Lyu, Chinbing; Kambayashi, Yumi; Amagai, Ryo; Otsuka, Atsushi; Fujisawa, Yasuhiro; Yoshino, Koji; Matsushita, Shigeto; Uchi, Hiroshi; Yamamoto, Yuki; Hata, Hiroo; Funakoshi, Takeru; Nonomura, Yumi; Tanaka, Ryota; Okuhira, Hisako; Wada, Naoko; Hashimoto, Akira; Aiba, Setsuya.

In: Frontiers in Medicine, Vol. 6, No. APR, 86, 01.01.2019.

Research output: Contribution to journalArticle

Fujimura, T, Sato, Y, Tanita, K, Lyu, C, Kambayashi, Y, Amagai, R, Otsuka, A, Fujisawa, Y, Yoshino, K, Matsushita, S, Uchi, H, Yamamoto, Y, Hata, H, Funakoshi, T, Nonomura, Y, Tanaka, R, Okuhira, H, Wada, N, Hashimoto, A & Aiba, S 2019, 'Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma', Frontiers in Medicine, vol. 6, no. APR, 86. https://doi.org/10.3389/fmed.2019.00086
Fujimura, Taku ; Sato, Yota ; Tanita, Kayo ; Lyu, Chinbing ; Kambayashi, Yumi ; Amagai, Ryo ; Otsuka, Atsushi ; Fujisawa, Yasuhiro ; Yoshino, Koji ; Matsushita, Shigeto ; Uchi, Hiroshi ; Yamamoto, Yuki ; Hata, Hiroo ; Funakoshi, Takeru ; Nonomura, Yumi ; Tanaka, Ryota ; Okuhira, Hisako ; Wada, Naoko ; Hashimoto, Akira ; Aiba, Setsuya. / Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma. In: Frontiers in Medicine. 2019 ; Vol. 6, No. APR.
@article{f51645d9338e4f6189c68d5cab0cb985,
title = "Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma",
abstract = "Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.",
keywords = "Baseline levels of CXCL5, Melanoma, Nivolumab, Nivolumab and ipilimumab combined therapy, Prediction of efficacy",
author = "Taku Fujimura and Yota Sato and Kayo Tanita and Chinbing Lyu and Yumi Kambayashi and Ryo Amagai and Atsushi Otsuka and Yasuhiro Fujisawa and Koji Yoshino and Shigeto Matsushita and Hiroshi Uchi and Yuki Yamamoto and Hiroo Hata and Takeru Funakoshi and Yumi Nonomura and Ryota Tanaka and Hisako Okuhira and Naoko Wada and Akira Hashimoto and Setsuya Aiba",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fmed.2019.00086",
language = "English",
volume = "6",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Association of baseline serum levels of CXCL5 with the efficacy of nivolumab in advanced melanoma

AU - Fujimura, Taku

AU - Sato, Yota

AU - Tanita, Kayo

AU - Lyu, Chinbing

AU - Kambayashi, Yumi

AU - Amagai, Ryo

AU - Otsuka, Atsushi

AU - Fujisawa, Yasuhiro

AU - Yoshino, Koji

AU - Matsushita, Shigeto

AU - Uchi, Hiroshi

AU - Yamamoto, Yuki

AU - Hata, Hiroo

AU - Funakoshi, Takeru

AU - Nonomura, Yumi

AU - Tanaka, Ryota

AU - Okuhira, Hisako

AU - Wada, Naoko

AU - Hashimoto, Akira

AU - Aiba, Setsuya

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

AB - Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since this combined therapy leads to a high frequency of serious immune-related adverse events (irAEs) in patients with advanced melanoma, biomarkers are needed to evaluate nivolumab efficacy to avoid serious irAEs caused by ipilimumab. This study analyzed baseline serum levels of CXCL5, CXCL10, and CCL22 in 46 cases of advanced cutaneous melanoma treated with nivolumab. Baseline serum levels of CXCL5 were significantly increased in responders compared to non-responders. In contrast, there were no significant differences of baseline serum levels of CXCL10 and CCL22 between responders and non-responders. These results suggest that baseline serum levels of CXCL5 may be useful as a biomarker for screening patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

KW - Baseline levels of CXCL5

KW - Melanoma

KW - Nivolumab

KW - Nivolumab and ipilimumab combined therapy

KW - Prediction of efficacy

UR - http://www.scopus.com/inward/record.url?scp=85064708367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064708367&partnerID=8YFLogxK

U2 - 10.3389/fmed.2019.00086

DO - 10.3389/fmed.2019.00086

M3 - Article

VL - 6

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

IS - APR

M1 - 86

ER -